Related Experiment Video

Updated: Apr 27, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K

BETs abet Tam-R in ER-positive breast cancer

Prasanna G Alluri1, Irfan A Asangani2, Arul M Chinnaiyan3

  • 11] Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Cell Research
|July 9, 2014
PubMed

Insights

Targeting epigenetic reader proteins like BRD2/3/4 offers a promising strategy for cancer treatment. This approach is particularly relevant for overcoming resistance to therapies such as tamoxifen in breast cancer.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Epigenetic modifications, including histone acetylation, are crucial for regulating genes driving cancer development.
  • Epigenetic reader proteins, such as BRD2/3/4, are increasingly recognized as critical targets in cancer therapy.

Purpose of the Study:

  • To explore the therapeutic potential of targeting epigenetic reader proteins (BRD2/3/4) in various cancers.
  • To investigate this strategy for overcoming tamoxifen resistance in breast cancer.

Main Methods:

  • Pharmacological modulation of BRD2/3/4 activity.
  • Analysis of gene expression and epigenetic changes.
  • In vitro and in vivo cancer models, including tamoxifen-resistant breast cancer.

Main Results:

  • Demonstrated that targeting BRD2/3/4 can inhibit oncogenic drivers.
  • Showcased the efficacy of this approach in overcoming tamoxifen resistance.
  • Identified specific epigenetic mechanisms affected by BRD2/3/4 modulation.

Conclusions:

  • Pharmacological targeting of BRD2/3/4 represents a viable therapeutic strategy for cancers.
  • This approach holds significant promise for treating tamoxifen-resistant breast cancer.
  • Further research into epigenetic reader proteins could lead to novel cancer treatments.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

28.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K